{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T18:50:08Z","timestamp":1793213408415,"version":"4.5.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T00:00:00Z","timestamp":1748476800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T00:00:00Z","timestamp":1748476800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"DOI":"10.1186\/s12876-025-04030-7","type":"journal-article","created":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T19:04:59Z","timestamp":1748545499000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Neoadjuvant chemotherapy with or without PD-1\/PD-L1 inhibitors in resectable esophageal squamous cell carcinoma: a meta-analysis based on randomized controlled trials"],"prefix":"10.1186","volume":"25","author":[{"given":"Ye","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fenglian","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenxiong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingmei","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,29]]},"reference":[{"issue":"1","key":"4030_CR1","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74(1):12\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"10466","key":"4030_CR2","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.1016\/S0140-6736(24)02226-8","volume":"404","author":"H Yang","year":"2024","unstructured":"Yang H, Wang F, Hallemeier CL, Lerut T, Fu J. Oesophageal cancer. Lancet. 2024;404(10466):1991\u20132005.","journal-title":"Lancet"},{"issue":"23","key":"4030_CR3","doi-asserted-by":"publisher","first-page":"2677","DOI":"10.1200\/JCO.20.00866","volume":"38","author":"MA Shah","year":"2020","unstructured":"Shah MA, Kennedy EB, Catenacci DV, Deighton DC, Goodman KA, Malhotra NK, et al. Treatment of locally advanced esophageal carcinoma: ASCO guideline. J Clin Oncol. 2020;38(23):2677\u201394.","journal-title":"J Clin Oncol"},{"issue":"10","key":"4030_CR4","doi-asserted-by":"publisher","first-page":"e2440568","DOI":"10.1001\/jamanetworkopen.2024.40568","volume":"7","author":"WJ Jeon","year":"2024","unstructured":"Jeon WJ, Park D, Al-Manaseer F, Chen YJ, Kim JY, Liu B, et al. Survival and treatment patterns in stage II to III esophageal cancer. JAMA Netw Open. 2024;7(10):e2440568.","journal-title":"JAMA Netw Open"},{"issue":"1","key":"4030_CR5","doi-asserted-by":"publisher","first-page":"9097","DOI":"10.1038\/s41467-024-52977-0","volume":"15","author":"Z Yang","year":"2024","unstructured":"Yang Z, Tian H, Chen X, Li B, Bai G, Cai Q, et al. Single-cell sequencing reveals immune features of treatment response to neoadjuvant immunochemotherapy in esophageal squamous cell carcinoma. Nat Commun. 2024;15(1):9097.","journal-title":"Nat Commun"},{"issue":"10","key":"4030_CR6","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1016\/j.ccell.2024.09.008","volume":"42","author":"X Shang","year":"2024","unstructured":"Shang X, Xie Y, Yu J, Zhang C, Zhao G, Liang F, et al. A prospective study of neoadjuvant pembrolizumab plus chemotherapy for resectable esophageal squamous cell carcinoma: the keystone-001 trial. Cancer Cell. 2024;42(10):1747\u2013e17637.","journal-title":"Cancer Cell"},{"issue":"1","key":"4030_CR7","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s12916-023-02804-y","volume":"21","author":"Y Li","year":"2023","unstructured":"Li Y, Zhou A, Liu S, He M, Chen K, Tian Z, et al. Comparing a PD-L1 inhibitor plus chemotherapy to chemotherapy alone in neoadjuvant therapy for locally advanced ESCC: a randomized phase II clinical trial: a randomized clinical trial of neoadjuvant therapy for ESCC. BMC Med. 2023;21(1):86.","journal-title":"BMC Med"},{"issue":"9","key":"4030_CR8","doi-asserted-by":"publisher","first-page":"2549","DOI":"10.1038\/s41591-024-03064-w","volume":"30","author":"J Qin","year":"2024","unstructured":"Qin J, Xue L, Hao A, Guo X, Jiang T, Ni Y, et al. Neoadjuvant chemotherapy with or without camrelizumab in resectable esophageal squamous cell carcinoma: the randomized phase 3 ESCORT-NEO\/NCCES01 trial. Nat Med. 2024;30(9):2549\u201357.","journal-title":"Nat Med"},{"key":"4030_CR9","doi-asserted-by":"publisher","first-page":"1139990","DOI":"10.3389\/fonc.2023.1139990","volume":"13","author":"S Wang","year":"2023","unstructured":"Wang S, Xu G, Li M, Zheng J, Wang Y, Feng X, et al. M1 macrophage predicted efficacy of neoadjuvant camrelizumab combined with chemotherapy vs chemotherapy alone for locally advanced ESCC: a pilot study. Front Oncol. 2023;13:1139990.","journal-title":"Front Oncol"},{"issue":"10","key":"4030_CR10","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1002\/cac2.12604","volume":"44","author":"Y Zheng","year":"2024","unstructured":"Zheng Y, Liang G, Yuan D, Liu X, Ba Y, Qin Z, et al. Perioperative toripalimab plus neoadjuvant chemotherapy might improve outcomes in resectable esophageal cancer: an interim analysis of a phase III randomized clinical trial. Cancer Commun (Lond). 2024;44(10):1214\u201327.","journal-title":"Cancer Commun (Lond)"},{"issue":"7","key":"4030_CR11","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1038\/s41416-024-02805-5","volume":"131","author":"YY Chen","year":"2024","unstructured":"Chen YY, Wang PP, Hu Y, Yuan Y, Yang YS, Shi HS, et al. Clinical efficacy and immune response of neoadjuvant camrelizumab plus chemotherapy in resectable locally advanced oesophageal squamous cell carcinoma: a phase 2 trial. Br J Cancer. 2024;131(7):1126\u201336.","journal-title":"Br J Cancer"},{"issue":"9","key":"4030_CR12","doi-asserted-by":"publisher","first-page":"5905","DOI":"10.1097\/JS9.0000000000001660","volume":"110","author":"IW Chen","year":"2024","unstructured":"Chen IW, Yu TS, Hung KC. Benefit of neoadjuvant immunotherapy plus chemotherapy in locally advanced esophageal squamous cell carcinoma: trial sequential analysis. Int J Surg. 2024;110(9):5905\u20136.","journal-title":"Int J Surg"},{"issue":"1","key":"4030_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","volume":"17","author":"AR Jadad","year":"1996","unstructured":"Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17(1):1\u201312.","journal-title":"Control Clin Trials"},{"key":"4030_CR14","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JP Higgins","year":"2011","unstructured":"Higgins JP, Altman DG, G\u00f8tzsche PC, J\u00fcni P, Moher D, Oxman AD, et al. The Cochrane collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.","journal-title":"BMJ"},{"issue":"4","key":"4030_CR15","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.jclinepi.2010.09.011","volume":"64","author":"GH Guyatt","year":"2011","unstructured":"Guyatt GH, Oxman AD, Sch\u00fcnemann HJ, Tugwell P, Knottnerus A. GRADE guidelines: a new series of articles in the journal of clinical epidemiology. J Clin Epidemiol. 2011;64(4):380\u20132.","journal-title":"J Clin Epidemiol"},{"issue":"2","key":"4030_CR16","doi-asserted-by":"publisher","first-page":"e234","DOI":"10.1097\/SLA.0000000000005701","volume":"278","author":"S Matsuda","year":"2023","unstructured":"Matsuda S, Kitagawa Y, Okui J, Okamura A, Kawakubo H, Takemura R, et al. Nationwide validation study of the prognostic significance of stratification using pathological stage and response to neoadjuvant chemotherapy for esophageal squamous cell carcinoma. Ann Surg. 2023;278(2):e234\u20139.","journal-title":"Ann Surg"},{"key":"4030_CR17","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.ejca.2023.03.008","volume":"186","author":"H Wang","year":"2023","unstructured":"Wang H, Jiang Z, Wang Q, Wu T, Guo F, Xu Z, et al. Pathological response and prognostic factors of neoadjuvant PD-1 blockade combined with chemotherapy in resectable oesophageal squamous cell carcinoma. Eur J Cancer. 2023;186:196\u2013210.","journal-title":"Eur J Cancer"},{"issue":"9","key":"4030_CR18","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1038\/s41419-024-06986-y","volume":"15","author":"Z Zhou","year":"2024","unstructured":"Zhou Z, Zhang H, Du J, Yang J, Pan W, Zhang Q, et al. A spatiotemporal comparative analysis on tumor immune microenvironment characteristics between neoadjuvant chemotherapy and preoperative immunotherapy for ESCC. Cell Death Dis. 2024;15(9):663.","journal-title":"Cell Death Dis"},{"issue":"10","key":"4030_CR19","doi-asserted-by":"publisher","first-page":"4896","DOI":"10.62347\/ELRQ9964","volume":"14","author":"K Yang","year":"2024","unstructured":"Yang K, Gao F, Zhou C, Cao S, Chai S, Li L. Immunological biomarkers and predictive model for recurrence of esophageal squamous cell carcinoma after combined immunotherapy and neoadjuvant chemotherapy. Am J Cancer Res. 2024;14(10):4896\u2013908.","journal-title":"Am J Cancer Res"},{"issue":"1","key":"4030_CR20","doi-asserted-by":"publisher","first-page":"e003497","DOI":"10.1136\/jitc-2021-003497","volume":"10","author":"W Yang","year":"2022","unstructured":"Yang W, Xing X, Yeung SJ, Wang S, Chen W, Bao Y, et al. Neoadjuvant programmed cell death 1 blockade combined with chemotherapy for resectable esophageal squamous cell carcinoma. J Immunother Cancer. 2022;10(1):e003497.","journal-title":"J Immunother Cancer"},{"key":"4030_CR21","doi-asserted-by":"publisher","first-page":"1453176","DOI":"10.3389\/fimmu.2024.1453176","volume":"15","author":"H Cai","year":"2024","unstructured":"Cai H, Chen L, Huang J, Ma H, Zhang S, Zhong K, et al. Mid-term follow-up results of neoadjuvant sintilimab combined with chemotherapy for locally advanced resectable esophageal squamous cell carcinoma. Front Immunol. 2024;15:1453176.","journal-title":"Front Immunol"},{"issue":"13","key":"4030_CR22","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1111\/1759-7714.15291","volume":"15","author":"Y Zhang","year":"2024","unstructured":"Zhang Y, Li H, Yu B, Sun S, Hu Z, Wu X, et al. Neoadjuvant chemoimmunotherapy for locally advanced esophageal squamous cell carcinoma: data from literature review and a real-world analysis. Thorac Cancer. 2024;15(13):1072\u201381.","journal-title":"Thorac Cancer"},{"key":"4030_CR23","doi-asserted-by":"publisher","first-page":"1456193","DOI":"10.3389\/fimmu.2024.1456193","volume":"15","author":"J Feng","year":"2024","unstructured":"Feng J, Wang L, Yang X, Chen Q. Adjuvant immunotherapy after neoadjuvant immunochemotherapy and esophagectomy for esophageal squamous cell carcinoma: a real-world study. Front Immunol. 2024;15:1456193.","journal-title":"Front Immunol"},{"issue":"3","key":"4030_CR24","doi-asserted-by":"publisher","first-page":"554","DOI":"10.3390\/cancers14030554","volume":"14","author":"H Teixeira Farinha","year":"2022","unstructured":"Teixeira Farinha H, Digklia A, Schizas D, Demartines N, Sch\u00e4fer M, Mantziari S. Immunotherapy for esophageal cancer: state-of-the art in 2021. Cancers (Basel). 2022;14(3):554.","journal-title":"Cancers (Basel)"},{"issue":"10","key":"4030_CR25","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1007\/s00432-024-06004-w","volume":"150","author":"P Wang","year":"2024","unstructured":"Wang P, Chen Y, Lei M, He H, Zhang D, Lin J, et al. Comparison of neoadjuvant chemoimmunotherapy and neoadjuvant chemotherapy for resectable esophageal squamous cell carcinoma: a retrospective study with 3-year survival analysis. J Cancer Res Clin Oncol. 2024;150(10):477.","journal-title":"J Cancer Res Clin Oncol"},{"key":"4030_CR26","doi-asserted-by":"publisher","first-page":"112558","DOI":"10.1016\/j.intimp.2024.112558","volume":"138","author":"Y Guo","year":"2024","unstructured":"Guo Y, Xu X, Wang T, Liu Y, Gu D, Fang Y, et al. Efficacy, safety, and survival of neoadjuvant immunotherapy plus chemotherapy in locally advanced esophageal squamous cell carcinoma: a real-world retrospective study. Int Immunopharmacol. 2024;138:112558.","journal-title":"Int Immunopharmacol"},{"issue":"7","key":"4030_CR27","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1111\/1759-7714.14795","volume":"14","author":"Y Yang","year":"2023","unstructured":"Yang Y, Li H, Chen X, Qin J, Li Y, Shen Y, et al. Comparison of neoadjuvant nab-paclitaxel plus immunotherapy versus paclitaxel plus immunotherapy for esophageal squamous cell carcinoma. Thorac Cancer. 2023;14(7):700\u20138.","journal-title":"Thorac Cancer"},{"issue":"Pt A","key":"4030_CR28","doi-asserted-by":"publisher","first-page":"112845","DOI":"10.1016\/j.intimp.2024.112845","volume":"142","author":"N Song","year":"2024","unstructured":"Song N, Wang Z, Sun Q, Xin G, Yao Z, Huang A, et al. Efficacy, safety, and prognostic modeling in neoadjuvant immunotherapy for esophageal squamous cell carcinoma. Int Immunopharmacol. 2024;142(Pt A):112845.","journal-title":"Int Immunopharmacol"},{"issue":"10","key":"4030_CR29","doi-asserted-by":"publisher","first-page":"7029","DOI":"10.21037\/jtd-24-1279","volume":"16","author":"L Cheng","year":"2024","unstructured":"Cheng L, Wang X, Shen H, Wang J, Yang Y, Wu W, et al. Safety and feasibility of neoadjuvant chemoradiotherapy combined with immunotherapy for locally advanced esophageal squamous cell carcinoma: a prospective single-group phase II clinical study. J Thorac Dis. 2024;16(10):7029\u201341.","journal-title":"J Thorac Dis"},{"issue":"1","key":"4030_CR30","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.jtcvs.2024.06.020","volume":"169","author":"X Yang","year":"2025","unstructured":"Yang X, Yin H, Zhang S, Jiang T, Gu J, Jiao H, et al. Perioperative outcomes and survival after neoadjuvant immunochemotherapy for locally advanced esophageal squamous cell carcinoma. J Thorac Cardiovasc Surg. 2025;169(1):289\u2013e3006.","journal-title":"J Thorac Cardiovasc Surg"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-025-04030-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-025-04030-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-025-04030-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T19:05:00Z","timestamp":1748545500000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgastroenterol.biomedcentral.com\/articles\/10.1186\/s12876-025-04030-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,29]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4030"],"URL":"https:\/\/doi.org\/10.1186\/s12876-025-04030-7","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,29]]},"assertion":[{"value":"18 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"As a systematic review and meta-analysis, our study did not require any human participation and, referral to our ethics committee.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"416"}}